Obecure Completes Patient Enrollment for Its Confirmatory Phase IIb Trial with HistaleanTM in Obesity
Published: Jan 20, 2009
RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure Ltd announced the completion of enrollment in its Phase IIb clinical trial, BET-207, evaluating the safety and efficacy of HistaleanTM for weight loss in obesity. The double-blinded, randomized, placebo-controlled, dose ranging study is designed to evaluate the drug in about 180 pre-menopause obese women. The study is intended to confirm and extend previous Phase II findings suggesting strong gender and age dependence and a significant response in females, aged =50 years, treated with 48 mg/day HistaleanTM. The co-primary endpoints for these studies are the mean percent weight loss and the percentage of subjects achieving weight loss of 5% or more.